Language:

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

The New England journal of medicine, 2016-12, Vol.375 (22), p.2144-2153 [Peer Reviewed Journal]

Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1604304 ;PMID: 27959767

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Author: Ference, Brian A ; Robinson, Jennifer G ; Brook, Robert D ; Catapano, Alberico L ; Chapman, M. John ; Neff, David R ; Voros, Szilard ; Giugliano, Robert P ; Davey Smith, George ; Fazio, Sergio ; Sabatine, Marc S
Subjects: Analysis ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - genetics ; Cholesterol ; Cholesterol, LDL ; Cholesterol, LDL - blood ; Clinical trials ; Coenzyme A ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus - genetics ; Female ; Genetic Predisposition to Disease ; Genetic Variation ; Health risk assessment ; Humans ; Hydroxymethylglutaryl CoA Reductases - genetics ; Hydroxymethylglutaryl-CoA reductase ; Kexin ; Low density lipoprotein ; Male ; Medical research ; Middle Aged ; Proprotein Convertase 9 - genetics ; Proprotein convertases ; Random Allocation ; Risk ; Risk factors ; Statins ; Subtilisin
Is Part Of: The New England journal of medicine, 2016-12, Vol.375 (22), p.2144-2153
Description: Statins are known to lower levels of LDL cholesterol, protect against cardiovascular disease, and slightly increase the risk of type 2 diabetes. This analysis of genetic variants in 112,772 participants from 14 studies suggests that PCSK9 inhibitors may do the same. Monoclonal antibodies and other therapies that inhibit proprotein convertase subtilisin–kexin type 9 (PCSK9) have been shown to reduce low-density lipoprotein (LDL) cholesterol levels by approximately 50 to 60% in several randomized trials. 1 – 8 Whether lowering LDL cholesterol levels by inhibiting PCSK9 will reduce the risk of cardiovascular events and, like statins, also increase the risk of new-onset diabetes is unknown. 9 Exploratory and post hoc analyses of randomized trials have suggested that lowering LDL cholesterol levels by approximately 70 mg per deciliter (1.81 mmol per liter) with a PCSK9 inhibitor may reduce the risk of major cardiovascular events by up to . . .
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1604304
PMID: 27959767
Source: ProQuest One Psychology
AUTh Library subscriptions: ProQuest Central
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1604304 ;PMID: 27959767

Searching Remote Databases, Please Wait